This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Establish an integrated UK Rare Disease Research Platform: nodes


Supporting Information

The Medical Research Council (MRC) and the NIHR is co-funding this opportunity to coordinate, network and enable research in rare diseases through a new national platform. 

Call opens: 19 August 2022
Call closes: 8 November 2022


Apply for funding to coordinate and address tractable challenges in rare diseases and achieve a step change in the mechanistic understanding, diagnosis and therapy of rare diseases.

You must be based at a UK research organisation eligible for MRC funding.

This is the outline stage.

Nodes must:

  • provide coordination as part of a wider UK Rare Disease Research Platform
  • connect the full spectrum of basic, clinical and translational research to stakeholders
  • enable focused progress on defined topics.

MRC and the NIHR will fund £12 million in total, for around 10 nodes.

The full economic cost of each node can be up to £1.25 million. We typically fund 80% of the full economic cost.

Funding is available for five years.


The MRC and the NIHR will be holding a webinar to support this funding opportunity on Wednesday 7 September 2022 at 14:00.
Register to attend the webinar.

UK Rare Disease Research Platform

The UK Rare Disease Research Platform is being established to support the diverse UK strengths in rare disease research.

The aim is to underpin greater collaboration between academic, clinical and industry research and patients, research charities and other stakeholders to accelerate the understanding, diagnosis and therapy of rare diseases. Rare diseases are defined as a disease with prevalence of less than one in 2,000 individuals, and including those with genetic and non-genetic origins.

The platform will bring together a number of challenge-led thematic nodes with a central platform hub (commissioned separately) to support networking and activities that enable research. 


Email address for queries: